Eton Pharmaceuticals, Inc.

Connor Clark and Lunn Investment Management Ltd. purchased a new stake in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,150 shares of the company's stock, valued at approximately $476,000. Other large investors have also

BlackRock Inc. bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,895,833 shares of the company's stock, valued at approximately $68,629,000. BlackRock Inc. owned about 6.92% of Eton Pharmaceuticals at the

Bank of America Corp DE boosted its holdings in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) by 37.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 144,367 shares of the company's stock after purchasing an additional 39,571 shares

Bank of Nova Scotia acquired a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,200 shares of the company's stock, valued at approximately $623,000. Bank of Nova Scotia owned about